Thiel's 6 Million Share Sale Casts a Shadow Over Palantir's Stellar Growth as AGM Nears

Palantir's 85% revenue jump and strong Q2 guidance clash with heavy insider selling by Peter Thiel and shareholder governance proposals, leaving stock down 19% year-to-date.

Palantir faces a pivotal week with two very different narratives colliding. While the data analytics powerhouse continues to deliver explosive revenue growth, insider selling — most notably by co-founder Peter Thiel — and a shareholder meeting laden with governance proposals are keeping investors on edge. The stock has already felt the strain, closing Friday in Frankfurt at €115.38, down 19.37% since the start of the year and 35.85% off its 52-week high.

On Tuesday, management sits down with Rosenblatt analyst John McPeake in New York, a session to be webcast at 1:45 p.m. ET. The timing is delicate. Rosenblatt raised its price target on Palantir to $225 in early May, citing the company’s ontology layer as a key competitive moat. Wedbush is even more bullish at $230, while RBC Capital holds at $90 and DA Davidson recently cut its target from $180 to $165. That kind of spread underscores the valuation tension that has defined the stock.

The operational story remains impressive. First-quarter revenue jumped 85% year over year to $1.63 billion, with adjusted earnings per share hitting $0.33 — a 154% leap. It was the eleventh consecutive quarter of accelerating revenue growth. For Q2, management guided for roughly $1.8 billion in revenue, well above the prior consensus of $1.68 billion. The backlog also looks robust, with remaining performance obligations totalling $4.45 billion and 206 contracts each worth over $1 million.

But the valuation multiplier leaves no room for error. Palantir trades at a very high multiple of expected earnings, making it vulnerable to any hint of a slowdown, margin pressure, or political headwinds. The technical picture reflects that caution: the stock sits below both its 50-day moving average of €124.15 and its 200-day line of €139.63, while the RSI at 54.3 signals no oversold condition.

Insider transactions have added to the unease. Over the past three months, the ratio of sales to purchases stood at 9.3 to 1. Peter Thiel alone sold 6 million shares during that period, including more than 2 million in a single day in March at prices between $140.97 and $146.80. While such sales are not inherently alarming — executives often sell for tax or liquidity reasons — they create a jarring contrast when paired with a string of blowout earnings.

The governance front heats up at the June 3 annual general meeting, where two shareholder proposals will test management's relationship with institutional investors. The first calls for greater disclosure around due diligence in defence contracts; the second demands a human rights impact assessment. Palantir's board recommends voting against both, arguing the company is not a data or surveillance firm and citing legal constraints on sharing certain details. The push comes from activist investors and religious orders, backed by organisations like Investor Advocates for Social Justice. In February, New York's comptroller also called for an independent review of human rights risks tied to Palantir’s work with the Department of Homeland Security and ICE.

Some large institutions have already voted with their feet. The Dutch pension fund ABP exited its position, and public pension funds in several US states face pressure from beneficiaries to do the same. The question is whether these governance concerns will begin to weigh on demand from government and defence clients — a core growth driver.

The next hard checkpoint arrives August 3, when Palantir reports second-quarter results. To maintain momentum, it must hit its own revenue range of $1.797 billion to $1.801 billion and demonstrate that the ethical debate has not dented its ability to convert a massive backlog into real sales. Until then, the stock remains caught between a sizzling business and a punishing valuation, with Thiel's share sales and the AGM providing two more reasons for the market to stay cautious.